Midatech Pharma PLC
LSE:MTPH
Midatech Pharma PLC
LSE:MTPH
Price:
15.1
GBX
1 489.47%
Market Cap:
£26.2m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Midatech Pharma PLC
LSE:MTPH
|
UK |
|
K
|
KBC Corporation Ltd
SSE:688598
|
CN |
|
Star Equity Holdings Inc
NASDAQ:STRR
|
US |
|
Immobiliere Dassault SA
PAR:IMDA
|
FR |
|
B
|
Bergenbio ASA
OSE:BGBIO
|
NO |
|
I
|
Isracard Ltd
TASE:ISCD
|
IL |
|
Suzhou Zelgen Biopharmaceuticals Co Ltd
SSE:688266
|
CN |
|
C
|
Canadian Net Real Estate Investment Trust
XTSX:NET.UN
|
CA |
|
First Quantum Minerals Ltd
TSX:FM
|
CA |
|
Divi's Laboratories Ltd
NSE:DIVISLAB
|
IN |
|
Saudi Arabian Cooperative Insurance Company SJSC
SAU:8100
|
SA |
|
Taiwan Taffeta Fabric Co Ltd
TWSE:1454
|
TW |
Multiples-Based Value
There is not enough data to reliably calculate the multiples-based value of MTPH.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
MTPH
Multiples-Based Value
Base Case
Not Available
Multiples Across Competitors
MTPH Competitors Multiples
Midatech Pharma PLC Competitors
Midatech Pharma PLC Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| UK |
|
Midatech Pharma PLC
LSE:MTPH
|
26.2m GBP | 45.3 | -4.8 | -3.1 | -2.9 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
373.2B USD | 6.1 | 89.5 | 14.8 | 20.6 | |
| US |
|
Exact Sciences Corp
NASDAQ:EXAS
|
356.4B USD | 6.2 | -96.2 | 951.3 | -107.4 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
190.4B USD | 5.2 | 24.6 | 14.3 | 14.3 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
169.9B USD | 5.8 | 20 | 12.5 | 15.4 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
115.2B USD | 9.5 | 28.7 | 21.6 | 22.5 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80B USD | 5.5 | 17.6 | 13.1 | 14.9 | |
| AU |
|
CSL Ltd
ASX:CSL
|
69.6B AUD | 3.2 | 34.9 | 11.5 | 14.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
